Radius announces update on tymlos® (abaloparatide) label

Boston, dec. 23, 2021 (globe newswire) -- radius health, inc. (“radius” or the “company”) (nasdaq: rdus) today announced that the u.s. food and drug administration (fda) has approved updates to the tymlos label, including the removal of the boxed warning regarding the risk of osteosarcoma.
RDUS Ratings Summary
RDUS Quant Ranking